Live Breaking News & Updates on Ares Genetics Gmbh

Stay updated with breaking news from Ares genetics gmbh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections


Published: Apr 19, 2021
Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021
Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) OpGen, Inc.
 (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is being extended beyond the second-year expansion phase by another six months through September 30, 2021.
Having successfully achieved all of the milestones of the first and second year phases for the development of an infectious disease digital health and precision medicine platform that connects health ....

New York , United States , Matthew Bretzius , Megan Paul , Oliver Schacht , Curetis Gmb , Opgen Acuitas , Department Of Health New York , Technology Platform , Health Wadsworth Center , Edison Group , Wadsworth Center Laboratories , Wadsworth Center Deputy , York State Department Of Health , Gene Panel , Wadsworth Center , Centers For Disease , Opgen Press Contact , York State Department , Research Use Only , Opgen Inc , Exchange Commission , Opgen Acuitas Lighthouse Software , Acuitas Lighthouse Software , Securities Exchange , Acuitas Lighthouse ,

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020


OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020
GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Thursday, March 25, 2021. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
Conference Call Details 
 
13717232
Following the conclusion of the conference call, a replay will be available through April 8, 2021. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the ....

United States , Matthew Bretzius , Megan Paul , Oliver Schacht , Curetis Gmb , Opgen Press Contact , Technology Platform , Opgen Inc , Edison Group , International Number , Gene Panel , Dial In Number , Curetis Gmbh , Ares Genetics Gmbh , Gen Press Contact , Tank Marketing , Gen Investor Contact , ஒன்றுபட்டது மாநிலங்களில் , மேகன் பால் , ஆலிவர் ஸ்ச்சித் , தொழில்நுட்பம் நடைமேடை , எடிசன் குழு , சர்வதேச எண் , கீந் குழு , டயல் செய்யுங்கள் இல் எண் , ஏரிஸ் ஜெநெடிக்ஸ் கஂப் ,

OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of .
OpGen, Inc.March 8, 2021 GMT
Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients
High negative predictive value of 99.8% may allow for reduction in unnecessary antibiotic use and support antibiotic stewardship efforts
Performance data, comprehensive coverage and turnaround time of less than 5 hours from sample to result of this panel
provides clinicians earlier data to inform antimicrobial decisions, especially in critically ill COVID-19 patients during flu season ....

United States , Baden Wuberg , Matthew Bretzius , Megan Paul , Opgen Unyvero , Oliver Schacht , Mackenziee Collins , Matthias Klein , Curetis Gmb , Technology Platform , Opgen Inc , Edison Group , Exchange Commission , Securities Exchange , Gene Panel , Karolinska Institutet Study , Unyvero Hospitalized Pneumonia , European Journal , Clinical Microbiology , Infectious Diseases , Unyvero Lower Respiratory Panels , Unyvero Hospital Acquired , Curetis Gmbh , Ares Genetics Gmbh , Looking Statements , Securities Act ,